The Impact of Artificial Intelligence on Value-Based Care in Orthopaedics

By Michael Awood

October 6, 2023

In healthcare, artificial intelligence has made considerable strides. It has the potential to enhance prediction, diagnosis, and decision-making. Researchers in orthopaedic surgery, where AI technologies have the potential to alter the discipline, have also seen this.

They can apply artificial intelligence in orthopaedics to find trends in data. Predicting patient risk potential or bad occurrences, for example, offers clinicians with crucial information. Despite the label “experimental,” there is mounting evidence that AI is successful and suitable for widespread use.

AI can help physicians and patients collaborate in the next steps. This points to a more cooperative intelligence. Physicians can give patient-specific risk-benefit ratios by feeding patient-reported outcomes into machine-learning algorithms. Doctors can use machine-learning algorithms to expect the results or advantages of arthroplasty surgery. However, we need further research to determine how these choice aids improve outcomes and provide value.

AI use in healthcare is fraught with ethical, legal, regulatory, and practise considerations. How should we get patients’ consent for AI-enabled robotic-assisted procedures? Surgeons must work with programmers to verify that the algorithm outputs match the demands of the patients.

It also poses questions regarding the current medical education programme, ultimately suggesting a redesign. Future professionals must learn to interact with and adapt to this technology for safe use in clinical settings.

However, there is a significant value proposition for AI in healthcare, particularly in terms of cost. AI technologies have the potential to reduce expenses by saving time and resources. These also impact patients’ experiences and outcomes. Getting clinician buy-in for the cultural shift, as well as assessing the initial cost, are essential concerns to balance against these potential savings.

AI has enormous potential in orthopaedics. To explore how artificial intelligence may aid orthopaedic patients, we need to test and assess it in clinics, prioritising its worth. According to the article, value is determined by weighing the advantages of new instruments against their entire expenses.

 

Cover image: stefamerpik on freepik

Reference url

Recent Posts

Fabhalta C3 glomerulopathy treatment
       

Fabhalta C3 glomerulopathy treatment Gains EMA Endorsement as First Targeted Therapy

💡 Have you heard the latest on treatment options for rare kidney diseases?

Novartis’ Fabhalta (iptacopan) has received a positive opinion from the EMA, potentially paving the way for the first approved treatment for C3 glomerulopathy. This first-in-class therapy showed a remarkable 35.1% reduction in proteinuria, promising improved outcomes for patients facing this progressive condition.

Curious about the implications for healthcare and the economy? Dive into the full article to learn how Fabhalta could reshape the landscape for patients with C3G and other complement-mediated diseases.

#SyenzaNews #HealthcareInnovation #DrugDevelopment #MarketAccess

TLX250-CDx imaging agent
      

Zircaix: A Potential Breakthrough in Kidney Cancer Diagnosis

🔍 Could a new imaging agent revolutionize kidney cancer diagnosis?

The FDA’s acceptance of the Biologics License Application for TLX250-CDx marks a significant milestone in the fight against clear cell renal cell carcinoma (ccRCC). This investigational PET imaging tool promises non-invasive, high-accuracy diagnostics, which could lead to improved patient outcomes and better-targeted treatment plans.

Curious about its potential impact on healthcare and market dynamics? Dive into the full article to learn more!

#SyenzaNews #medicalimaging #oncology #HealthcareInnovation

personalized cancer vaccine
         

Personalized Cancer Vaccine in High-Risk Kidney Cancer Patients

🌟 Could personalized cancer vaccines be the future of cancer treatment?

A recent phase I clinical trial has shown promising results for a personalized cancer vaccine in patients with high-risk clear cell renal cell carcinoma (RCC). All participants developed immune responses, and notably, none experienced recurrence at a median follow-up of over 40 months! With a favorable safety profile, this approach may pave the way for more effective adjuvant therapies in oncology.

Jump into the full findings and see how this advancement could change the landscape of cancer treatment!

#SyenzaNews #oncology #biotechnology #innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.